Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus DOXAZOSIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus DOXAZOSIN MESYLATE.
ALFUZOSIN HYDROCHLORIDE vs DOXAZOSIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker